Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-9187

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-9187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of duloxetine hydrochloride, showing the molecular framework with aromatic rings, a sulfur-containing heterocycle, and hydrochloride indicated alongside.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between Duloxetine delayed-release capsules and placebo treatments. The x-axis represents time in days up to about 200, and the y-axis shows the proportion of patients with relapse ranging from 0 to 1. Duloxetine shows a consistently lower proportion of relapse compared to placebo throughout the time period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time between placebo and Duloxetine delayed-release capsules. The x-axis shows time from randomization to relapse in days, ranging from 0 to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. The graph includes two lines: a dashed line for placebo and a solid line for Duloxetine delayed-release capsules, indicating lower relapse proportions for the Duloxetine group throughout the study period.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups labeled DUL 60 mg BID, DUL 60 mg QD, DUL 20 mg QD, and Placebo, with each group represented by different markers and lines. The vertical axis shows percentage of patients improved, while the horizontal axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: DUL 60mg BID, DUL 60mg QD, and placebo, illustrating patient response levels across increasing pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement distribution across varying pain improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph displaying percentage of patients improved against percent improvement in pain from baseline. It compares four groups: DUL 120 mg once daily, DUL 60 mg once daily, DUL 20 mg once daily, and placebo, showing the relationship between dosage and pain improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for two groups: placebo and DUL 60/120 mg once daily. The graph shows a higher percentage of patients improved with DUL 60/120 mg across various levels of pain improvement compared to placebo.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The graph shows separate data lines for placebo and Duloxetine, with improvement percentages plotted along the vertical axis and pain improvement percentages on the horizontal axis.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent placebo (cross markers) and Duloxetine (diamond markers).*

FDA Label Image

Label (Lbl636299187)

Label for Duloxetine Delayed-Release Capsules, USP 40 mg, by Bryant Ranch Prepack. The label includes the NDC 63629-9187-01, a barcode, and instructions to keep out of reach of children. It states each capsule contains 44.9 mg Duloxetine Hydrochloride USP equivalent to 40 mg Duloxetine. The package contains 30 capsules for oral use and includes pharmacist dispensing instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.